- Tags: ARVO
Events
ARVO 2026 signals a turning point for retina innovations
Highlights from this year’s research in vision and ophthalmology meeting covered genetics, gene editing, AI, advanced imaging, and more.
Pipeline
New SightGlass 24-month data shows DOT lenses significantly slow pediatric myopia progression
Unveiled at ARVO 2026, DOT lenses saved more than 1 D of myopic progression on average after 2 years among 6-to-10-year-old wearers.
Products
ARVO 2026: Heidelberg debuts new ophthalmic imaging and data management tech
Medtech company premiers still-investigational imaging platform with OCT, a fully digitally surgical microscope, and additions to the HEYEX 2 platform.
Research
Could oral contraceptives lead to retinal thinning?
Duration of oral contraceptive use mediated the impact on retinal morphology.
Research
New data supports Hoya's DIMS lenses for myopic prevention among preschool-aged pediatrics
Presented at ARVO, updated findings among the younger pre-myopics confirmed a protective effect of the patented and embedded technology on refractive status.
Products
Zeiss debuts new research data platform for integrated workflows
Company’s cloud-based solution uses AI technology to integrate accessible clinical and research data into clinicians’ daily routines.
Pipeline
Favorable safety data supports Alkeus' oral gildeuretinol for dry AMD
Presented during ARVO 2025, the modified form of Vitamin A demonstrated a slower decline in vision-related quality of life among patients diagnosed with GA secondary to AMD.Products
Heidelberg showcases fully digital surgical visualization platform
The SeeLuma features an ergonomically-friendly design, 3D technology, and a new intraoperative OCT module, among other add-ons, for surgeons.
Research
Could insulin eye drops provide corneal healing?
Researchers share new findings on the effectiveness of insulin therapy for neurotrophic keratitis.
Research
How accurate are consumer reviews of OTC eye care products?
Cross-sectional study analyzes 210 of the top products sold on Amazon and store retailers.
Research
Could ranibizumab be more effective for ROP than laser therapy?
RAINBOW extension study evaluates 5-year outcomes for ranibizumab 0.2 mg and 0.1 mg vs YAG laser therapy in improving visual acuity.
Research
New data on Eylea HD supports prolonged dosing for wet AMD
Presented at ARVO, 96-week extending dosing supports reduced need for frequent injections.
Research
Researchers detect first dry eye-specific genetic locus
Chart review of genome-wide association studies enables the development and validation of a DED phenotyping algorithm.
Research
J&J's new IRD global registry targets real-world data accessibility
First-of-its-kind, real-world data research registry has the potential to offer more insight into disease progression and future treatments.
Research